Could a cancer drug ease diabetes in kids with rare fat disease?
NCT ID NCT03936829
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether cyclophosphamide, a drug that calms the immune system, can reduce insulin needs in people with a rare condition that causes fat loss (lipodystrophy) and type 1 diabetes. Ten participants will receive the treatment, and researchers will measure how much insulin they need to keep blood sugar in a healthy range. The goal is to see if the drug can improve the body's response to insulin, not to cure the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIPODYSTROPHY ACQUIRED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital of Fudan University
Shanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new sensor track blood sugar with pinpoint accuracy?
- Can a Normal-Weight baseline improve heart risk assessment in type 1 diabetes?
- Carb showdown: which diet best controls type 1 diabetes?
- Morning workout may burn more fat and stabilize blood sugar in type 1 diabetes
- Could a simple sugar help people with type 1 diabetes exercise safely?
- New study asks: is this glucose monitor a Game-Changer for diabetes?